Clinical evaluation of rush immunotherapy using house dust mite allergen in Japanese asthmatics

Takahiro Uchida; Kazuyuki Nakagome; Hidetoshi Iemura; Erika Naito; Sachiko Miyauchi; Yoshitaka Uchida; Tomoyuki Soma; Makoto Nagata

doi:10.5415/apallergy.2021.11.e32

Clinical evaluation of rush immunotherapy using house dust mite allergen in Japanese asthmatics

Asia Pac Allergy. 2021 Jul 19;11(3):e32. doi: 10.5415/apallergy.2021.11.e32. eCollection 2021 Jul.

Authors

Takahiro Uchida¹, Kazuyuki Nakagome¹, Hidetoshi Iemura¹, Erika Naito¹, Sachiko Miyauchi¹, Yoshitaka Uchida¹, Tomoyuki Soma¹, Makoto Nagata¹

Affiliation

¹ Department of Respiratory Medicine and Allergy Center, Saitama Medical University, Saitama, Japan.

Abstract

Background: Allergen immunotherapy (AIT) is a specific treatment of administering clinically important allergens to patients who have allergic diseases. In Japan, the standardized house dust mite (HDM) allergen for subcutaneous immunotherapy (SCIT) was approved in 2015, and we then introduced rush-immunotherapy (rush-IT) using the standardized HDM allergen for HDM-sensitive asthmatics. However, little data are available on the safety and effectiveness of rush-HDM-IT, especially for Japanese asthmatics.

Objective: The objective of this study was to examine the safety and clinical effectiveness of rush-IT using the standardized HDM for HDM-sensitive Japanese asthmatics.

Methods: Thirteen HDM-sensitive asthmatics who received rush-HDM-IT and 12 HDM-sensitive asthmatic controls were enrolled. To evaluate the safety, the number of systemic reaction (SR) events, including anaphylaxis, was assessed. To evaluate the effectiveness, changes in the treatment step, dose of inhaled corticosteroid, and asthma control after rush-HDM-IT and the subsequent maintenance SCIT were assessed. Changes in the HDM-induced production of type 2 cytokines from peripheral blood mononuclear cells were also evaluated.

Results: Among the 12 patients who received rush-IT, 4 (30.7%) experienced a SR and 3 (23.1%) experienced anaphylaxis. However, the anaphylaxis was not severe (grade 3) in all cases, and they recovered in a short time. The treatment step of asthma was better and the dose of inhaled corticosteroid was lower in the rush-HDM-IT group than in the control group. The HDM-induced production of both interleukin (IL)-5 and IL-13 from peripheral blood mononuclear cells was significantly lower in the rush-HDM-IT group than in the control group.

Conclusion: Rush-HDM-IT can be performed relatively safely in Japanese asthmatics. Furthermore, rush-HDM-IT and the subsequent maintenance SCIT provided clinical improvement in asthma patients, and was accompanied by the suppression of HDM-specific Th2-mediated systemic immune responses.

Keywords: Allergen immunotherapy; Bronchial asthma; House dust mite; Rush immunotherapy; Subcutaneous immunotherapy.